NewKerala.com

Biocon Founder Kiran Mazumdar-Shaw Names Niece Claire as Successor, Report Says

Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as her successor to lead Biocon, as reported in a Fortune India interview. Claire, currently CEO of Bicara Therapeutics, has a strong academic background from MIT and Stanford. A broader family ecosystem, including Claire’s brother and husband, may support the company. Biocon is undergoing organizational changes, including merging generics and biologics, to focus on biosimilars.

Key Points: Biocon Founder Kiran Mazumdar-Shaw Names Niece as Successor

  • Kiran Mazumdar-Shaw names niece Claire Mazumdar as Biocon successor
  • Claire is founder and CEO of Bicara Therapeutics
  • Family ecosystem includes brother Eric Mazumdar and husband Thomas Roberts
  • Biocon merges generics and biologics, focuses on biosimilars
2 min read

Biocon founder Kiran Mazumdar-Shaw names niece Claire as successor: Report

Kiran Mazumdar-Shaw names her niece Claire Mazumdar as successor to lead Biocon into its next growth phase, with a formal succession plan outlined.

"I am the sole owner of Biocon, and I need to make sure that I put it in good hands. - Kiran Mazumdar-Shaw"

New Delhi, May 5

Biocon founder Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as her successor, outlining a formal succession plan for the biopharmaceutical company, a report said on Tuesday.

In an interview with Fortune India, Mazumdar-Shaw (73) said she sees Claire (37) as the right person to lead Biocon, a leading biopharmaceutical firm, into its next phase of growth.

"I am the sole owner of Biocon, and I need to make sure that I put it in good hands. I have seen my niece Claire as my successor because I think she has proved to me that she can run a company," she said.

Claire Mazumdar, who is currently the founder and CEO of Bicara Therapeutics, a Nasdaq-listed company incubated by Biocon.

Mazumdar-Shaw -- who has no children -- said a broader family ecosystem could also support the company's future growth.

This includes Claire's brother Eric Mazumdar, a professor at the California Institute of Technology and an AI expert, as well as her husband Thomas Roberts, an oncologist at Massachusetts General Hospital.

As part of a wider organisational overhaul, Biocon has merged its generics and biologics businesses, simplified its structure, and reduced debt. The company is sharpening its focus on biosimilars, which contribute a significant share of revenue, with several products already in the market and more in the pipeline, Mazumdar-Shaw said.

Moreover, the chosen successor holds a degree in Biological Engineering from the Massachusetts Institute of Technology, an MBA from Stanford Graduate School of Business, and a PhD in Cancer Biology from Stanford School of Medicine.

The report also highlighted that leadership transitions are also underway across group companies.

It added that Shreehas Tambe has taken over as CEO and Managing Director of Biocon Biologics, while Siddharth Mittal is set to lead Syngene International from July 1.

Shares of Biocon were trading over 1 per cent higher at Rs 365.55 on the BSE on Tuesday.

- IANS

Share this article:

Reader Comments

R
Rohit P
Nice to see a woman-led succession plan in Indian pharma. Kiran Mazumdar-Shaw is a true pioneer. But I hope the broader family ecosystem doesn't create governance issues later. Need to keep it professional.
V
Vikram M
Claire Mazumdar is already a CEO of a Nasdaq-listed company at 37. That's no small feat. Biocon is in good hands. The biosimilar focus is also smart — that's where the future of affordable healthcare lies.
A
Ananya R
Kiran Mazumdar-Shaw has always been a role model for Indian women entrepreneurs. This succession plan is well thought-out. The mention of AI expert brother and oncologist husband in the ecosystem adds a futuristic touch. Exciting times for Biocon!
S
Sarah B
As someone who follows global pharma, this is a smart move. Kiran is ensuring continuity while bringing in fresh expertise. The MIT/Stanford pedigree is solid. But let's see how Claire handles the Indian market dynamics separately from Bicara.
K
Kavya N
Great decision by Kiran Mazumdar-Shaw. She's ensured the legacy continues without any corporate drama. The restructuring and debt reduction also show she's serious about future growth. Best wishes to Claire! 🙌
J
James A

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50